Rexahn raises $5.3M for cancer drugs; Neuraltus seeks $30M for Lou Gehrig's development;

@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce

@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce

@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce

> Rexahn Pharmaceuticals ($RNN) has signed a deal to sell $5.3 million in securities through a direct offering, cash it'll use to develop the cancer drugs Archexin, RX-3117, and RX-5902. News

> Are this year's beneficiaries of the biotech IPO boom doomed to tank when investors' lock-up periods expire? OncoMed Pharmaceutials ($OMED) CEO Paul Hastings advises companies how to maintain value. Interview

> Bay Area biotech Neuraltus Pharmaceuticals is raising $30 million to fund a Phase II study of a treatment for Lou Gehrig's disease. More

Medical Device News

@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> St. Jude Medical CEO knocks rival and regulatory climate, but also offers optimism. More

> Gov't shutdown halts FCC's wireless med tech certification. Item

> Bipartisan backing of device tax repeal threatened by gov't funding fight. Story

> German-U.S. team test intestinal tube implant to treat obesity. Article

Pharma News

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@EricPFierce: spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce

@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce

> Fresenius punished distributor for selling its drug for executions. Report

> J&J, AstraZeneca take Zytiga to Japan. Article

> FDA signoff on Ranbaxy NJ plant may provide drugmaker relief. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.